Thesis
A fluorogenic hypoxia-activated prodrug strategy for targeted compound delivery and imaging of tumours
- Abstract:
-
Hypoxia, a common feature in solid tumours, is associated with aggressive phenotypes, decreased genomic stability, and with increased resistance to all forms of cancer therapy. The significant differences between the hypoxic microenvironment, and normal tissues, present a therapeutic opportunity through the design of bioreductive hypoxia-activated prodrugs (HAPs). This strategy aids the selective delivery of chemotherapeutics to hypoxic regions, reducing their effects in non-hypoxic tissue...
Expand abstract
Actions
Funding
Cancer Research UK
More from this funder
Medical Research Council UK
More from this funder
Bibliographic Details
- Type of award:
- DPhil
- Level of award:
- Doctoral
- Awarding institution:
- University of Oxford
Item Description
- UUID:
-
uuid:f3084a0e-1665-4442-955d-82ba6e5b321f
- Deposit date:
- 2016-12-03
Related Items
Terms of use
- Copyright holder:
- O'Connor, L
- Copyright date:
- 2016
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record